Novel therapeutics in development for the treatment of stimulant-use disorder

被引：4
|
作者：
Young, Erica J. [1 ,2 ,3 ]
Radnai, Laszlo [1 ,2 ]
Prikhodko, Victor [3 ]
Miller, Courtney A. [1 ,2 ]
机构：
[1] Herbert Wertheim UF Scripps Inst Biomed Innovat &, Dept Mol Med, Jupiter, FL 33458 USA
[2] Herbert Wertheim UF Scripps Inst Biomed Innovat &, Dept Neurosci, Jupiter, FL 33458 USA
[3] Myosin Therapeut, Jupiter, FL USA
来源：
CURRENT OPINION IN NEUROBIOLOGY | 2024年 / 87卷
关键词：
METHAMPHETAMINE MONOCLONAL-ANTIBODY; CONTINGENCY MANAGEMENT; RECEPTOR ANTAGONISTS; SYNAPTIC PLASTICITY; SUBSTANCE-USE; MYOSIN IIB; COCAINE; COMBINATION; INVOLVEMENT; METYRAPONE;
D O I：
10.1016/j.conb.2024.102898
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Misuse and accidental overdoses attributed to stimulants are escalating rapidly. These stimulants include methamphetamine, cocaine, amphetamine, ecstasy-type drugs, and prescription stimulants such as methylphenidate. Unlike opioids and alcohol, there are no therapies approved by the US Food and Drug Administration (FDA) to treat stimulant- use disorder. The high rate of relapse among this population highlights the insufficiency of current treatment options, which are limited to abstinence support programs and behavioral modification therapies. Here, we briefly outline recent regulatory actions taken by FDA to help support the development of new stimulant use disorder treatments and highlight several new therapeutics in the clinical development pipeline.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] Screen of drug use: Diagnostic accuracy for stimulant use disorder
    Tiet, Quyen Q.
    Moos, Rudolf H.
    ADDICTIVE BEHAVIORS, 2021, 112
  • [42] STIMULANT TREATMENT OF PEDIATRIC TOURETTE DISORDER AND ADHD
    CASTELLANOS, FX
    GULOTTA, CS
    TANAKA, J
    RITCHIE, G
    ELIA, J
    RAPOPORT, JL
    BIOLOGICAL PSYCHIATRY, 1993, 33 (6A) : A42 - A43
  • [43] Novel investigational therapeutics for panic disorder
    Perna, Giampaolo
    Schruers, Koen
    Alciati, Alessandra
    Caldirola, Daniela
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (04) : 491 - 505
  • [44] Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease
    Kelleher, Catherine
    Kocinsky, Hetal
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2020, 27 (02) : 95 - 103
  • [45] Development of novel peptidic therapeutics for the treatment of sickle cell disease
    Wynn, Cody G.
    Brennan, Brian B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [46] Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection
    Hu, Yimin
    Zhu, Wei
    Tang, Guozhi
    Mayweg, Alexander V.
    Yang, Guang
    Wu, Jim Z.
    Shen, Hong C.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 48, 2013, 48 : 265 - 281
  • [47] Alcohol Use Disorder: Neurobiology and Therapeutics
    Yang, Waisley
    Singla, Rohit
    Maheshwari, Oshin
    Fontaine, Christine J.
    Gil-Mohapel, Joana
    BIOMEDICINES, 2022, 10 (05)
  • [48] Oxytocin, a Novel Treatment for Methamphetamine Use Disorder
    Edinoff, Amber N.
    Thompson, Elliot
    Merriman, Chandler E.
    Alvarez, Mark R.
    Alpaugh, E. Saunders
    Cornett, Elyse M.
    Murnane, Kevin S.
    Kozinn, Rachel L.
    Shah-Bruce, Mila
    Kaye, Adam M.
    Kaye, Alan D.
    NEUROLOGY INTERNATIONAL, 2022, 14 (01) : 186 - 198
  • [49] Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
    Palis, Heather
    MacDonald, Scott
    Jun, Jennifer
    Oviedo-Joekes, Eugenia
    HARM REDUCTION JOURNAL, 2021, 18 (01)
  • [50] Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
    Heather Palis
    Scott MacDonald
    Jennifer Jun
    Eugenia Oviedo-Joekes
    Harm Reduction Journal, 18
12345